Arcutis Biotherapeutics, Inc. (ARQT) Q2 FY26 Earnings Call

Rising prescription demand drove a 2026 guidance raise, while commercial expansion and pediatric opportunities support further growth [7].

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-05
Length67 minutes
EPS$0.11
EPS consensus$0.09
Revenue$129.9M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25

All ARQT earnings ยท Back to ARQT overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.